First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2019-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-019-03796-4PMID 30915497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

  2018cited by this paper
• Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cited by this paper
• Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1

  2016cited by this paper
• Melanoma-expressed CD70 is involved in invasion and metastasis

  2015cited by this paper
• AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma

  2015cited by this paper
• First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70

  2015cited by this paper
• Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

  2014cited by this paper
• A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

  2013cited by this paper
• Non-compartmental analysis.

  2012cited by this paper
• CD70 expression patterns in renal cell carcinoma.

  2012cited by this paper
• Cytoskeletal mechanics of proplatelet maturation and platelet release

  2010cited by this paper
• Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

  2006cited by this paper
• CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding

  2006cited by this paper
• Induction of CD70 on Dendritic Cells through CD40 or TLR Stimulation Contributes to the Development of CD8+ T Cell Responses in the Absence of CD4+ T Cells1

  2005cited by this paper
• CD70: a new tumor specific biomarker for renal cell carcinoma.

  2005cited by this paper
• Practical Implementation of Bayesian Dose-Escalation Procedures

  2003cited by this paper
• CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors

  2002cited by this paper
• CD70 expression in thymic carcinoma.

  2000cited by this paper
• Bayesian decision procedures based on logistic regression models for dose-finding studies.

  1998cited by this paper
• Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells.

  1995cited by this paper
• CD70 represents the human ligand for CD27.

  1994cited by this paper
• Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor.

  1993cited by this paper

• Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems

  2025cites this paper
• Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years?

  2025cites this paper
• Efficacy and safety of antibody-drug conjugates in the treatment of advanced urological cancers: a systematic review and a meta-analysis

  2025cites this paper
• CD70: An emerging target for integrated cancer diagnosis and therapy

  2025influential citation
• Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment

  2025cites this paper
• The CD70-CD27 axis in cancer immunotherapy: Predictive biomarker and therapeutic target.

  2025cites this paper
• A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study

  2025cites this paper
• Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy

  2025cites this paper
• CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2024cites this paper
• ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study

  2024cites this paper
• Renal cancer: signaling pathways and advances in targeted therapies

  2024cites this paper
• Molecular imaging of renal cell carcinomas: ready for prime time

  2024cites this paper
• CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond.

  2024cites this paper
• Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy

  2024cites this paper
• Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives

  2023influential citation
• Exploration of the antibody–drug conjugate clinical landscape

  2023cites this paper
• Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities

  2023cites this paper
• Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer

  2023cites this paper
• Current status and future prospects of antibody–drug conjugates in urological malignancies

  2022cites this paper
• The CD70-CD27 axis in oncology: the new kids on the block

  2022cites this paper
• Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current Clinical Trials and Future Directions

  2022cites this paper
• Advances in Research on Pharmacokinetics of Antibody-drug Conjugates

  2021cites this paper
• Stepping forward in antibody-drug conjugate development.

  2021cites this paper
• New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)

  2020cites this paper
• An up-to-date overview of computational polypharmacology in modern drug discovery

  2020cites this paper
• Current State of Systemic Therapies for Advanced Renal Cell Carcinoma

  2020cites this paper